Clinical trials: Amyloidosis, Familial
Cardiac Amyloidosis
Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
Tne aim purpose of this observational, multicentre and propective study is to determine the prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older hospitalized within the last 12 months for heart failure…
- Trial name
- ARNOLD (NCT06427304)
- Where
- 36 sites in France
- Volunteers
- 637 people
- Sponsor
- Gérond'if
Transthyretin Amyloid Polyneuropathy
To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy
- Trial name
- NCT06940336
- Testing
- Tafamidis Meglumine Soft Capsules
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Amyloid Cardiomyopathy, Wild Type ATTR Amyloidosis
Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy
The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy.
- Trial name
- NCT06261216
- Testing
- Interview
- Where
- Austria
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Cardiac Amyloidosis
Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.
To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.
- Trial name
- AMYLCAR (NCT03232632)
- Testing
- PET with 18 F-Flutemetamol
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Toulouse
Amyloid, Amyloid Cardiomyopathy
18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis
Amyloidoses are systemic or acquired disorders characterized by the deposition in the extracellular spaces of amyloid fibers formed by proteins codified by mutated genes or non-mutated but misfolded proteins.
- Trial name
- PETAL (NCT06048601)
- Testing
- 18F-florbetaben PET/CT
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Toscana Gabriele Monasterio
Cardiac Amyloidosis
Cardiac Amyloidosis Registry of University Hospital Leipzig
This is a clinical registry of patients with cardiac amyloidosis being treated at University Hospital Leipzig. The aim of the registry is to collect detailed information about clinical events, symptoms, imaging, biomarkers…
- Trial name
- NCT06129656
- Testing
- Routine diagnostics, Routine treatment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Leipzig
Cardiac Amyloidosis
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy
Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR from other amyloidosis or…
- Trial name
- QUANTI-SUV (NCT04849754)
- Testing
- bone scintigraphy
- Where
- France
- Volunteers
- 30 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
ATTR Amyloidosis Wild Type
Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)
The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt).
- Trial name
- DobATTR (NCT06318260)
- Testing
- Dobutrex
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Steen Hvitfeldt Poulsen
Transthyretin (TTR) Amyloid Cardiomyopathy
Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study
The objective of this study is to determine the association of clinically prescribed, on-label, TTR stabilizing therapy (e.g. tafamidis or acoramidis) with levels of circulating transthyretin amyloid aggregates (TAAs, a surrogate…
- Trial name
- NCT07196839
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer's Disease
Dominantly Inherited Alzheimer Network (DIAN)
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
- Trial name
- DIAN (NCT00869817)
- Where
- 26 sites in United States, Argentina and 11 more
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Amyloid Cardiomyopathy
Open-Label Study of AG10 in Patients With Cardiomyopathy
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of acoramidis administered on a background of stable heart failure therapy.
- Trial name
- NCT03536767
- Testing
- Acoramidis
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Amyloidosis, Cardiac Amyloidosis
Study of Olfactory Disorders in Patients With Cardiac Amyloidosis
Amyloidosis is a disease caused by the continuous accumulation of fibrillary proteins in the extracellular matrix causing the architecture of different organs to be disrupted. The prevalence of the disease increases with age.
- Conditions
- Amyloidosis, Cardiac Amyloidosis, Olfactory Loss, Hyposmia
- Trial name
- AMYLODOR (NCT04661800)
- Testing
- Sniffin's stick test
- Where
- France
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy.
- Conditions
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies
- Trial name
- NCT02319005
- Testing
- Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
- Where
- 61 sites in United States, Belgium and 7 more
- Volunteers
- 206 people
- Sponsor
- Alnylam Pharmaceuticals
Familial Mediterranean Fever
AGE and CALLY Index in Familial Mediterranean Fever
Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent inflammatory attacks and persistent low-grade inflammation.
- Trial name
- NCT07439341
- Testing
- Skin Autofluorescence Measurement
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bursa City Hospital
Cardiac Amyloidosis
Identification of Prognostic Parameters in Patients With " Senile " Amyloid Cardiomyopathy
The aging of the population is a reality in our society, with a strong increase in the number of elderly patients hospitalized for heart failure in our institutions.
- Trial name
- EVAMYLOSE (NCT04225754)
- Where
- France
- Volunteers
- 142 people
- Sponsor
- University Hospital, Grenoble
Amyloidosis Cardiac
Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
This phase II clinical trial aimed at influencing the improvement of major organ functions, especially the objective response rate, in Amyloid light-chain amyloidosis involving myocardium.
- Trial name
- NCT04298372
- Testing
- Lenalidomide 25mg
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Seoul National University Hospital
Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR)
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture.
- Conditions
- Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR), Hypertrophic Cardiomyopathy (HCM)
- Trial name
- Amylo (NCT01623245)
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Thibaud Damy
TTR-mediated Amyloidosis
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
- Trial name
- NCT01961921
- Testing
- ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
- Where
- 9 sites in United States, Brazil and 5 more
- Volunteers
- 27 people
- Sponsor
- Alnylam Pharmaceuticals
Cardiac Amyloidosis
Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
Cardiac Amyloidosis (CA) is characterized by a long subclinical phase characterized by deposition of amyloid fibrils in atria, valves and walls of ventricles.
- Trial name
- NCT04387344
- Where
- 2 sites in Italy
- Volunteers
- 25 people
- Sponsor
- University of Messina
Transthyretin Cardiac Amyloidosis
EFICAC-TTR Trial: Exercise and Nutritional Supplementation in Transthyretin Cardiac Amyloidosis
Transthyretin cardiac amyloidosis (TTR-CA) is a systemic cardiac disease that predominantly affects older adults and is frequently associated with reduced physical capacity, muscle weakness, frailty, and impaired quality of life.
- Trial name
- EFICAC-TTR (NCT07343999)
- Testing
- Home-Based Multicomponent Exercise Program, Microcrystalline Cellulose Control Supplementation, Creatine and HMB Supplementation
- Where
- 3 sites in Spain
- Volunteers
- 47 people
- Sponsor
- Universidad de Burgos